Regression of Choroidal Metastasis of Non-small-cell Lung Cancer with Intravitreal Bevacizumab and Photodynamic Therapy.
- Author:
Jee Wook KIM
1
;
Sung Jin LEE
Author Information
1. Department of Ophthalmology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. wismile@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Bevacizumab;
Choroidal metastasis;
Non-small-cell lung cancer;
Photodynamic therapy
- MeSH:
Antibodies, Monoclonal, Humanized;
Choroid;
Eye;
Female;
Humans;
Lung;
Lung Neoplasms;
Neoplasm Metastasis;
Photochemotherapy;
Recurrence;
Retinal Detachment;
Triazenes;
Visual Acuity;
Bevacizumab
- From:Soonchunhyang Medical Science
2012;18(2):111-114
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 56-year-old female patient presented with decreased visual acuity in her right eye lasting for one day. During the first visit, best corrected visual acuity (BCVA) was 20/80 and 20/20, in the right and left eye, respectively. Fundus examination of the right eye revealed an elevated mass in the superior area of the optic disc and exudative retinal detachment in the macula. Choroidal metastatic tumor secondary to non-small-cell lung cancer (NSCLC) was diagnosed after systemic work up. Photodynamic therapy (PDT) and the intravitreal bevacizumab injection for choroidal metastatic carcinoma were performed. After six months, the BCVA of the right eye was improved to 20/25. Complete regression of the tumor was noticed and serous detachment was resolved. There has been no recurrence for six months. We observed that combined treatment with PDT and intravitreal bevacizumab injection is effective in BCVA improvement and tumor regression, in a patient with choroidal metastasis of NSCLC.
